XVIVO Perfusion Calls 2026 AGM, Proposes New Board Members and Incentive Plan

Xvivo Perfusion AB ( (SE:XVIVO) ) just unveiled an update.

XVIVO Perfusion AB has called its Annual General Meeting for 27 April 2026 in Gothenburg, Sweden, inviting shareholders who are registered with Euroclear Sweden or have arranged voting rights registration to participate. Shareholders may attend in person or via proxy, with formal notification procedures and documentation requirements detailed by the company.

The agenda includes adoption of the annual accounts, decisions on profit allocation and discharge from liability for the board and CEO, and the election and remuneration of board members and auditors. The nomination committee proposes re-election of several directors, the addition of two new board members, re-election of the chairman, and the introduction of a performance-based share option incentive program for group management and key personnel, signaling continued focus on governance stability and management incentives.

The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK191.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

More about Xvivo Perfusion AB

XVIVO Perfusion AB is a Swedish medtech company specializing in advanced perfusion systems and related technologies for organ transplantation. The company focuses on improving the preservation, assessment, and availability of organs for transplant, serving hospitals and transplant centers in a highly regulated global healthcare niche.

Average Trading Volume: 152,186

Technical Sentiment Signal: Sell

Current Market Cap: SEK5.72B

For a thorough assessment of XVIVO stock, go to TipRanks’ Stock Analysis page.